3Wang F,Song Y,Jiang Y,et al.Associations among peri-ostin gene polymorphisms,clinical parameters and heartfailure:a case-control study in 1 104 Chinese individu-als.. J Cardiovasc Med (Hagerstown) . 2011
4Alonso-Martinez JL,Lloren-Diez B,Echegaray-Agara M,et al.C-reactive protein as a predictor of improvementand readmission in heart failure. European Journal of Heart Failure . 2002
5Campbell DJ,Woodward M,Chalmers JP,et al.Predic-tion of myocardial infarction by N-terminal-pro-B-typenatriuretic peptide,C-reactive protein,and renin in sub-jects with cerebrovascular disease. Journal of Hypertension . 2005
6Anand IS,Latini R,Florea VG,et al.C-reactive protein in heart failure:prognostic value and the effect of valsartan. Circulation . 2005
7Azzazy HM,Christenson RH,Duh SH.Stability of B-type natriureticpeptide (BNP)in whole blood and plasma stored under different condi-tion when measured with the Biosite Triage or Beckman-Coulter Accesssystems. Clinica Chimica Acta . 2007
8Dao Q,Krishnaswamy P,Kazanegra R,et a.l Utility of B-type na-triuretic peptide in the d iagnosis of congestive heart failure in an ur-gent care setting. Journal of the American College of Cardiology . 2001
2LESTER S J, TAJIK A J, NISHIMURA R A, et al. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later[J]. J Am Coll Cardiol, 2008,51 : 679 - 689.
3ANVERSA P, NADAL-GINARD B. Myocene renewal and ventricular remodelling[J]. Nature, 2002, 415:240-243.
4The Task Force on Heart Failure of the European Society of Cardiology[J]. Guidelines for the diagnosis of heart failure[J]. Eur Heart J,1995,16:741-751.
5IWANAGAY, NISHI I, FURUICHI S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure[J]. J Am Coll Cardiol, 2006,47 : 742 - 748.
6CULLOUGH P A, OMLAND T, MAISEL A S. B- type natriuretic peptides: a diagnostic breakthrough for clinicians[J].Rev Cardiovasc Med, 2003,4 : 72 - 80.
7DAO Q, KRISHNASWAMY P, KAZANEGRA R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting[J]. J Am Coll Cardiol, 2001,37 :379- 385.
8Francis GS.Neurohumoral activation and progression of heart failure:hypothetical and clinical consideration.J Cardiovasc Pharmacol,1998,32(Suppl 1):16-21.
9Blum A,Miller H.The role of cytokine in heart failure.Am Heart J,1998,135:181-186.
10Jianhui Zhu,Quyyumi AA,Noman JE,et al.Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels.Am J Cardiol,2000,85:140-146.
7Xin W, Wei W, Li X. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a Meta-analysis of randomized controlled trials[J]. BMC Cardiovasc Disord, 2012,12:77.
8Siddiqi L, Joles JA, Oey PL, et al. Atorvastatin reduces sympa- thetic activity in patients with chronic kidney disease [J]. J Hypertens, 2011,29(11) :2176-2180.
9KozdagG, Ertas G, Kilic T, et al. Elevated level of high-sensi tivity C-reactive protein is important in determining prognosis in chronic heart failure[J]. Med Sci Monit, 2010, 16 (3): CR156-CR161.
10Greig D, Alcaino H, Castro PF, et al. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters[J]. J Heart Lung Transplant, 2011,30 (4) :408-413.
